SRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. SRE is sitting just below the key pivot (~87.94) with weakening momentum (negative MACD) and no Intellectia entry signals, while hedge funds and insiders have been net sellers recently. Options positioning is modestly bullish (calls outweigh puts), but activity is light and implied volatility is elevated vs realized—more consistent with uncertainty than strong conviction. I would wait rather than buy immediately.
Intellectia Proprietary Trading Signals
Trend/momentum: MACD histogram is negative (-0.138) and still below zero, indicating bearish-to-neutral momentum despite the contraction (selling pressure easing, but not reversed). RSI(6) ~45.9 is neutral, consistent with a choppy/sideways market rather than an uptrend. Moving averages are converging, which typically signals consolidation and a lack of a clean directional edge.
Levels: Price ~87 is below the pivot (87.944), so bulls have not reclaimed control. Nearby support is S1 ~84.64 (then S2 ~82.59). Upside resistance is R1 ~91.25 (then R2 ~93.30). For an “buy now” decision, the chart does not currently offer a strong trend-following entry; it’s more of a range setup with downside risk to support.
on 2026-02-24 pre-market could reset sentiment if guidance/earnings quality improves.
are not far away, so downside tests are plausible before a durable rebound.
Latest reported quarter: 2025/Q3. Revenue grew to $3.151B (+13.51% YoY), but profitability deteriorated sharply: Net income fell to $77M (-87.93% YoY) and EPS dropped to $0.12 (-88.00% YoY). Gross margin also declined to 64.74 (-7.70% YoY). Net-net: solid top-line growth, but major margin/earnings compression—this weakens the fundamental momentum going into the next print.
Recent trend: Price targets have been trimmed across several firms in January (UBS to $92 from $98; BMO to $100 from $103; Barclays to $97 from $98; Wells Fargo to $112 from $115), reflecting a more cautious near-term stance. Morgan Stanley raised its PT to $95 from $91 (still Overweight). Overall ratings skew constructive (Overweight/Outperform at multiple shops), but the direction of target changes lately is mostly downward.
Wall Street pros: (1) Regulated utility exposure with perceived longer-term execution upside, (2) some analysts view the recent pullback as overdone, (3) still multiple bullish ratings.
Wall Street cons: (1) litigation/regulatory headline risk (SoCalGas), (2) recent earnings/margin weakness, (3) targets being revised down suggests reduced near-term confidence.
Influential buying/selling: No recent Congress trading data available, and no politician/influential-figure trades were provided in the data.
